Key result
In patients undergoing breast cancer surgery treated with pharmacological thromboprophylaxis, the 30-day incidence of venous thromboembolic events was 0.7% and hemorrhagic events was 5.4%.
Why the study?
Venous thromboembolic disease causes substantial morbidity and mortality after breast cancer surgery, making it important to evaluate the need for systemic antithrombotic prophylaxis versus mechanical interventions and the optimal duration of chemoprophylaxis.
Population
540 patients undergoing breast cancer surgery
Comparison
Pharmacological prophylaxis with recommended mechanical prophylaxis
Design
Retrospective database analysis
Follow-up
30 days after surgery
Authors
Loading...
Pharmacological thromboprophylaxis was associated with low VTE but 5.4% bleeding after breast cancer surgery; leaves open optimal strategy in prospective studies.
Cohort (n=540)
No
In patients undergoing breast cancer surgery, pharmacological thromboprophylaxis is associated with a low rate of venous thromboembolism (0.7%) but a 5.4% incidence of hemorrhagic events.
Andrei et al. (2019) conducted a cohort in Breast cancer (n=540). Pharmacological thromboprophylaxis (LMWH) was evaluated on Venous thromboembolic events within 30 days after surgery (95% CI 0.02-1.9). In patients undergoing breast cancer surgery treated with pharmacological thromboprophylaxis, the 30-day incidence of venous thromboembolic events was 0.7% and hemorrhagic events was 5.4%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: